Xarelto improved portal hypertension complication-free survival in patients with cirrhosis and moderate liver dysfunction without an increase in major bleeding events, according to data presented at ...
Portal Hypertension Symptoms and Their ComplicationsPortal hypertension is a condition in which increased pressure within the portal vein—an important vessel that carries blood from the stomach and ...
Galectin Therapeutics is hosting a virtual key opinion leader (KOL) event to discuss the unmet needs in treating MASH cirrhosis and portal hypertension, positioning the company as a thought leader in ...
Galectin Therapeutics, Inc. announced results from its NAVIGATE trial, which evaluated belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal ...
Please provide your email address to receive an email when new articles are posted on . Sustained virologic response occurred in 81.8% of patients after the first DAA treatment course. Despite this, ...
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal ...
Body composition—the distribution of bone, muscle, and fat in the body—can yield vital information on the metabolic and nutritional status of a patient. Several studies have demonstrated the impact of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback